[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355154-105":59,"doc-detail-355154-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","clinical-impact-of-semaglutide-beyond-glycemic-control-a-critical-analysis-of-oncogenic-potential-and-mitigation-of-cardiotoxicity","Clinical Impact of Semaglutide Beyond Glycemic Control - A Critical Analysis of Oncogenic Potential and Mitigation of Cardiotoxicity","","Semaglutide, a GLP-1 receptor agonist, shows high efficacy in type 2 diabetes and obesity, yet its rapid adoption has raised long-term safety questions, especially regarding oncogenic risk and cardiovascular effects. This narrative review synthesizes recent clinical trials and post-marketing surveillance to assess links between semaglutide exposure and cancer incidence, and to evaluate whether semaglutide can reduce cardiotoxicity from anticancer therapies. Existing human data are generally reassuring, while ongoing monitoring remains warranted.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinical-impact-of-semaglutide-beyond-glycemic-control-a-critical-analysis-of-oncogenic-potential-and-mitigation-of-cardiotoxicity/355154/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinical-impact-of-semaglutide-beyond-glycemic-control-a-critical-analysis-of-oncogenic-potential-and-mitigation-of-cardiotoxicity/355154.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main purpose of this narrative review?","Question",{"text":112,"@type":113},"To analyze recent evidence from clinical trials and post-marketing surveillance on the relationship between semaglutide use and cancer incidence, and to evaluate its role in mitigating cardiotoxicity caused by anticancer therapies.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What do the review results suggest about cancer risk?",{"text":117,"@type":113},"Human epidemiological data are described as reassuring for most concerns, and current meta-analyses regarding pancreatic cancer do not confirm a significant risk increase, with metabolic benefits outweighing potential concerns.",{"name":119,"@type":110,"acceptedAnswer":120},"How does semaglutide relate to cardiotoxicity in complex clinical scenarios?",{"text":121,"@type":113},"The review highlights semaglutide’s cardioprotective and anti-inflammatory properties, suggesting it may help safeguard cardiovascular integrity during oncological treatments, while emphasizing continued oncological monitoring.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355154,1790690639,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Review  \nClinical Impact of Semaglutide Beyond Glycemic Control: A Critical Analysis of Oncogenic Potential and Mitigation of Cardiotoxicity  \nAdriana Correra 1,†, Alfredo Mauriello 2,†, Valeria Cetoretta 3, Anna Chiara Maratea 4, Lucia Riegler 5,  \nIsabella Di Sarno 6, Francesco Giallauria 7, Federico Guerra 3, Vincenzo Russo 8 and Antonello D’Andrea 5, *  \nAcademic Editor: Agnieszka Sliwinska  \nReceived: 25 January 2026  \nRevised: 8 February 2026  \nAccepted: 9 February 2026  \nPublished: 10 February 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Cardiology Department, Ospedali Riuniti University Hospital, Viale Pinto 1, 71122 Foggia, Italy; [adrianacorrera@gmail.com](adrianacorrera@gmail.com)  \n2 S.C. Cardiology, Institute National Cancer, IRCCS, Fondazione “G. Pascale”, Via M. Semmola 52,  \n80131 Naples, Italy; [alfredo.mauriello93@libero.it](alfredo.mauriello93@libero.it)  \n3 Cardiology and Arrhythmology Clinic, Marche Polytechnic University, University Hospital “Ospedali Riuniti”, Via Conca 71, 60126 Ancona, Italy; [vcetoretta@gmail.com](vcetoretta@gmail.com) (V.C.); [guerra.fede@gmail.com](guerra.fede@gmail.com) (F.G.)  \n4 Department of Cardiovascular Disease, ASL Napoli 1 Centro, Via Comunale del Principe, 13/a,  \n80145 Naples, Italy; [annachiara.maratea@gmail.com](annachiara.maratea@gmail.com)  \n5 Cardiology and Intensive Care Unit, Department of Cardiology,“Umberto I” Hospital, Via Alfonso De Nicola 1, 84014 Nocera Inferiore, Italy; [luciariegler@yahoo.it](luciariegler@yahoo.it)  \n6 UOSD Neurophysiopathology, AORN “Santobono Pausillipon”, Via Mario Fiore, 6, 80129 Naples, Italy; [isadisarno@gmail.com](isadisarno@gmail.com)  \n7 Department of Translational Medical Sciences,“Federico II” University of Naples, Via S. Pansini 5,  \n80131 Naples, Italy; [francesco.giallauria@unina.it](francesco.giallauria@unina.it)  \n8 Cardiology Unit, Department of Medical and Translational Sciences, University of Campania “Luigi Vanvitelli”,“V. Monaldi” Hospital, Via Leonardo Bianchi snc, 80131 Naples, Italy; [vincenzo.russo@unicampania.it](vincenzo.russo@unicampania.it)  \n* Correspondence: [antonellodandrea@libero.it](antonellodandrea@libero.it)[ ](antonellodandrea@libero.it)† These authors contributed equally to this work.  \nAbstract  \nIntroduction: Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has demonstrated unprecedented efficacy in the treatment of type 2 diabetes mellitus (T2DM) and obesity. However, its rapid clinical widespread use has ignited a debate regarding long-term safety, particularly concerning the risk of specific neoplasms and its ability to modulate cardiovascular health, not only as primary prevention but also as a potential agent to mitigate cardiotoxicity. Objectives: This narrative review aims to analyze the most recent evidence from clinical trials and post-marketing surveillance to evaluate the correlation between semaglutide use and the incidence of cancer, as well as the drug’s efficacy in reducing cardiotoxicity induced by anticancer therapies. Results and Discussion: While preclinical rodent models suggested a link to medullary thyroid carcinoma, human epidemiological data remain reassuring, though caution is advised in patients with genetic predisposition. Regarding pancreatic cancer, current meta-analyses do not confirm a significant increase in risk, suggesting that metabolic benefits outweigh potential concerns. Conclusions: Semaglutide is confirmed as a therapeutic tool with a highly favorable benefit– risk profile. While oncological monitoring must continue, the drug’s cardioprotective and anti-inflammatory properties open new frontiers not only in metabolic management but also in safeguarding cardiovascular integrity in complex clinical scenarios.  \nKeywords: semaglutide; GLP-1RA; oncogenesis; cardiotoxicity; cardiov","cbCail9cMp4ER1XT","https://ap.wps.com/l/cbCail9cMp4ER1XT","pdf",371859,"English","# Abstract\n# Introduction\n# Methods","[{\"question\":\"What is the main purpose of this narrative review?\",\"answer\":\"To analyze recent evidence from clinical trials and post-marketing surveillance on the relationship between semaglutide use and cancer incidence, and to evaluate its role in mitigating cardiotoxicity caused by anticancer therapies.\"},{\"question\":\"What do the review results suggest about cancer risk?\",\"answer\":\"Human epidemiological data are described as reassuring for most concerns, and current meta-analyses regarding pancreatic cancer do not confirm a significant risk increase, with metabolic benefits outweighing potential concerns.\"},{\"question\":\"How does semaglutide relate to cardiotoxicity in complex clinical scenarios?\",\"answer\":\"The review highlights semaglutide’s cardioprotective and anti-inflammatory properties, suggesting it may help safeguard cardiovascular integrity during oncological treatments, while emphasizing continued oncological monitoring.\"}]","Clinical Impact of Semaglutide Beyond Glycemic Control - A Critical Analysis of Oncogenic Potential and Mitigation of Cardiotoxicity | PDF",1790116372,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6ca2f99f34cccfb325b3719960f23c11.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/96b589fbccbfd937ca2298b0542121be.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/545dc37523fe655103e0ffc0897796cd.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0efff6e8b4ace80de51905724d6a323d.webp",980,1385]